Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial
The Oncologist · 07.10.2026 · 31 (11)
DOI: 10.1093/oncolo/oyag421 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift The Oncologist, online erschienen am 19.10.2026. Verfasst von Vivek Bhadri und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, NSW 2050, Australia. Hauptthemen laut MEDLINE: Giant Cell Tumor of Tendon Sheath, Protein Kinase Inhibitors. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deciphera Pharmaceuticals, LLC.
Abstract (Originalsprache)
Background
Tenosynovial giant cell tumor (TGCT) is a locally aggressive neoplasm caused by colony-stimulating factor 1 (CSF1) gene dysregulation. Vimseltinib is an oral, switch-control tyrosine kinase inhibitor of the CSF1 receptor. In part 1 of the MOTION phase 3 trial, vimseltinib demonstrated statistically significant and clinically meaningful improvements in antitumor activity and clinical outcome assessments (COAs). Here, we report long-term results from MOTION in patients with >2 years of follow-up on study.
Methods
MOTION is a randomized, double-blind, placebo-controlled, phase 3 trial with double-blind (part 1; to week 25), open-label (part 2; weeks 25-49), and extension periods (NCT05059262). Eligible adult patients with histologically confirmed TGCT not amenable to surgery received vimseltinib 30 mg twice weekly. Efficacy was assessed by objective response rate (ORR) on study evaluated by independent radiological review per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) and Tumor Volume Score. COAs and safety were assessed.
Results
In total, 118 patients received vimseltinib during MOTION (randomized to vimseltinib, n = 83; crossover, n = 35), with 51% (60/118) remaining on treatment. ORR on study per RECIST v1.1 was 48% (40/83) for patients randomized to vimseltinib and 54% (19/35) for crossover. Patients in both groups experienced long-term improvements in COAs. The safety profile was consistent with prior reports, with no evidence of cholestatic hepatotoxicity or drug-induced liver injury.
Conclusion
Vimseltinib continued to provide robust and durable antitumor activity and demonstrated long-term improvements in COAs, with manageable safety for the treatment of patients with TGCT not amenable to surgery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, NSW 2050, Australia.
- Department of Medical Oncology, Leiden University Medical Center, Leiden, ZA 2333, The Netherlands.
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 20133, Italy.
- Department of Medical Oncology and Sarcoma Center/West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, 45147, Germany.
- German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, 45147, Germany.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, United States.
ORCID-Profile: Vivek Bhadri, Hans Gelderblom, Silvia Stacchiotti, Sebastian Bauer, Andrew J Wagner, Michiel van de Sande, Nicholas M Bernthal, Antonio López Pousa, Antoine Italiano, Mahbubl Ahmed, Gabriel Tinoco, Kjetil Boye, Javier Martín-Broto, Emanuela Palmerini, Benjamin C Powers, Peter Reichardt, Piotr Rutkowski, Brooke Harrow, Maitreyi G Sharma, Jean-Yves Blay, William D Tap
Förderung
- Deciphera Pharmaceuticals, LLC
Zitieren
APA
Bhadri, V., Gelderblom, H., Stacchiotti, S., Bauer, S., Wagner, A. J., van de Sande, M., Bernthal, N. M., López Pousa, A., Abdul Razak, A., Italiano, A., Ahmed, M., Le Cesne, A., Tinoco, G., Boye, K., Martín-Broto, J., Palmerini, E., Tafuto, S., Pratap, S., Powers, B. C., …, & Tap, W. D. (2026). Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial. The Oncologist, 31(11). https://doi.org/10.1093/oncolo/oyag421
Vancouver
Bhadri V, Gelderblom H, Stacchiotti S, Bauer S, Wagner AJ, van de Sande M, et al. Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial. The Oncologist. 2026;31(11). doi:10.1093/oncolo/oyag421
BibTeX
@article{Bhadri2026,
author = {Bhadri, Vivek and Gelderblom, Hans and Stacchiotti, Silvia and Bauer, Sebastian and Wagner, Andrew J and van de Sande, Michiel and Bernthal, Nicholas M and López Pousa, Antonio and Abdul Razak, Albiruni and Italiano, Antoine and Ahmed, Mahbubl and Le Cesne, Axel and Tinoco, Gabriel and Boye, Kjetil and Martín-Broto, Javier and Palmerini, Emanuela and Tafuto, Salvatore and Pratap, Sarah and Powers, Benjamin C and Reichardt, Peter and Casado Herráez, Antonio and Rutkowski, Piotr and Tait, Christopher and Agnello, Giulia and Harrow, Brooke and Saunders, Amanda and Sharma, Maitreyi G and Sherman, Matthew L and Blay, Jean-Yves and Tap, William D},
title = {Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {11},
doi = {10.1093/oncolo/oyag421}
}
EUVIMED